Ipamorelin
Also known as: IPAM, NNC 26-0161
Growth Hormone Secretagogue~711.9 Da
A selective growth hormone secretagogue peptide studied for its ability to stimulate growth hormone release with fewer side effects compared to earlier secretagogues.
Ipamorelin is a selective growth hormone secretagogue (GHS) peptide that has drawn significant interest in both research and clinical practice. Among the growth hormone-releasing peptides, ipamorelin is noted for its selectivity in stimulating growth hormone release without substantially affecting cortisol or prolactin levels. This characteristic has made it one of the most commonly discussed growth hormone secretagogues in peptide therapy. Ipamorelin is not FDA-approved for any medical condition but is available through compounding pharmacies when prescribed by licensed physicians.
What Is Ipamorelin?
Ipamorelin is a synthetic pentapeptide consisting of five amino acids. It functions as a selective agonist of the growth hormone secretagogue receptor (GHS-R), also known as the ghrelin receptor. When ipamorelin binds to this receptor on pituitary cells, it stimulates the release of stored growth hormone in a pulsatile manner that mimics the body natural release pattern. Ipamorelin was originally developed by Novo Nordisk in the 1990s as part of research into more targeted growth hormone-releasing compounds. Its molecular weight is approximately 711.9 Da. What distinguishes ipamorelin from earlier growth hormone secretagogues like GHRP-6 and GHRP-2 is its reported selectivity, meaning it appears to stimulate growth hormone release with minimal effects on other hormones in the studies conducted to date.
How Ipamorelin Is Studied
Ipamorelin has been evaluated in both preclinical and limited clinical studies. Early clinical trials examined its effects on growth hormone release patterns, demonstrating dose-dependent increases in growth hormone levels without corresponding increases in cortisol, prolactin, or aldosterone. Research has also explored ipamorelin in the context of post-surgical ileus, where it showed potential for improving gastrointestinal recovery after bowel surgery. Body composition studies have examined the effects of growth hormone secretagogue-mediated GH elevation on lean body mass and fat distribution. However, large-scale phase III clinical trials establishing efficacy for specific conditions have not been completed, and ipamorelin did not progress through the full FDA approval process for any indication.
Proposed Mechanisms of Action
Ipamorelin exerts its effects by binding to the GHS-R1a receptor on somatotroph cells in the anterior pituitary gland. This binding triggers intracellular signaling cascades that result in the release of growth hormone from secretory granules. The growth hormone released then acts on tissues throughout the body, either directly or through stimulating hepatic production of insulin-like growth factor 1 (IGF-1). The downstream effects of elevated growth hormone and IGF-1 include potential influences on protein synthesis, fat metabolism, bone density, and cellular repair processes. Ipamorelin selectivity is thought to result from its specific receptor binding profile, which does not strongly activate the pathways responsible for cortisol or prolactin release that are stimulated by less selective secretagogues.
Common Goals Associated with Ipamorelin
In clinical practice, ipamorelin is most frequently discussed in relation to body composition goals, including muscle growth support and fat loss. Growth hormone influences both protein synthesis and lipolysis, making growth hormone optimization a topic of interest for patients with body composition objectives. Ipamorelin also appears in longevity and anti-aging discussions, as growth hormone levels naturally decline with age. Some patients seek ipamorelin therapy for sleep quality improvement, based on the connection between growth hormone pulsatility and deep sleep physiology. Recovery from training and exercise is another commonly cited goal.
How Clinics May Offer Ipamorelin Therapy
Peptide therapy clinics typically administer ipamorelin via subcutaneous injection, with many protocols calling for once-daily or twice-daily dosing. A common clinical approach involves evening administration to complement the natural nighttime growth hormone pulse. Treatment protocols usually include baseline and follow-up lab work to monitor growth hormone, IGF-1, and other relevant biomarkers. Some clinics prescribe ipamorelin as a standalone therapy, while others combine it with CJC-1295 for potentially enhanced growth hormone stimulation. Treatment durations vary but commonly span three to six months with periodic reassessment.
Safety and Regulatory Status
Ipamorelin is not FDA-approved for any medical indication. Available clinical data has shown a relatively favorable safety profile compared to other growth hormone secretagogues, with the most commonly reported side effects being transient headache and injection site reactions. The absence of significant cortisol and prolactin elevation is considered a safety advantage over earlier secretagogues. However, long-term safety data from controlled clinical trials is not available. Potential risks associated with chronic growth hormone elevation, including theoretical concerns about insulin resistance and effects on cell proliferation, have not been fully characterized for ipamorelin specifically. As with all compounded peptides, quality depends on the sourcing pharmacy, and patients should verify that their provider uses an FDA-registered compounding facility.
Comparison with Related Peptides
Ipamorelin is most directly compared to CJC-1295, with which it is frequently combined in clinical protocols. While ipamorelin acts on the ghrelin receptor (GHS-R), CJC-1295 acts on the growth hormone-releasing hormone receptor (GHRH-R). The combination rationale is that stimulating both pathways simultaneously may produce a greater growth hormone response than either peptide alone. Compared to GHRP-6 and GHRP-2 (earlier growth hormone secretagogues), ipamorelin is reported to have fewer effects on appetite, cortisol, and prolactin. Unlike BPC-157 and TB-500, which target tissue repair pathways, ipamorelin operates through the growth hormone axis. Semaglutide, as an FDA-approved GLP-1 receptor agonist, works through an entirely different mechanism and has a much more established regulatory and clinical evidence base.
Related Goals
Muscle Growth
Peptides researched for potential effects on lean body mass, growth hormone stimulation, and body composition improvements.
Fat Loss
Peptides studied for their potential effects on body composition, appetite regulation, and metabolic support in the context of weight management.
Sleep
Peptides studied for their potential effects on sleep quality, particularly through growth hormone pathway modulation during natural sleep cycles.
Longevity
Peptides under investigation for potential roles in cellular health, tissue maintenance, and age-related physiological changes.
Compare Related Peptides
BPC-157
A synthetic pentadecapeptide derived from a protective protein found in human gastric juice, investigated in preclinical research for tissue repair and gastrointestinal protection.
CJC-1295
A synthetic analog of growth hormone-releasing hormone (GHRH) designed for sustained growth hormone elevation through extended half-life.
Semaglutide
An FDA-approved GLP-1 receptor agonist prescribed for type 2 diabetes management and chronic weight management in eligible patients.
TB-500
A synthetic peptide fragment of thymosin beta-4, a naturally occurring protein involved in cell migration and tissue repair, studied primarily in preclinical research.
Find Peptide Clinics Near You
Peptide Clinics in Austin — Directory & Guide
Find peptide therapy clinics in Austin, TX. Compare providers, learn about treatments, and understand what to look for in an Austin peptide clinic.
Peptide Clinics in Los Angeles — Directory & Guide
Find peptide therapy clinics in Los Angeles. Compare providers, learn about treatments, and understand what to look for in an LA peptide clinic.
Peptide Clinics in Miami — Directory & Guide
Find peptide therapy clinics in Miami, FL. Compare providers, learn about available treatments, and understand what to look for in a Miami peptide clinic.
Peptide Clinics in New York — Directory & Guide
Find peptide therapy clinics in New York City. Compare providers, learn about treatments, and understand what to look for in a NYC peptide clinic.
Peptide Clinics in Scottsdale — Directory & Guide
Find peptide therapy clinics in Scottsdale, AZ. Compare providers, learn about treatments, and understand what to look for in a Scottsdale peptide clinic.
Further Reading
How to Evaluate a Peptide Clinic — A Patient's Checklist
Learn how to evaluate peptide therapy clinics. Understand what credentials to look for, red flags to avoid, and questions to ask before starting treatment.
Peptide Legality in the United States — What You Need to Know
Understand the legal status of peptides in the United States, including FDA regulations, compounding pharmacy rules, and state-level considerations.
Peptide Therapy Explained — How It Works
Understand how peptide therapy works, what to expect from treatment, and how to evaluate whether peptide therapy may be appropriate for you.
Research Peptides vs. Prescription Peptides — Key Differences
Understand the critical differences between research peptides and prescription peptides, including safety, legality, and quality considerations.
What Are Peptides? A Beginner's Guide
Learn what peptides are, how they work in the body, and why they are gaining attention in medical research and clinical practice.
Frequently Asked Questions
What does ipamorelin do?
Is ipamorelin FDA-approved?
Why is ipamorelin often combined with CJC-1295?
What are the side effects of ipamorelin?
When is the best time to take ipamorelin?
Last reviewed: 3/14/2026